Key Insights

Highlights

Success Rate

80% trial completion

Treatment Research

5 treatments under study, led by Amcenestrant

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

20.0%

1 terminated out of 5 trials

Success Rate

80.0%

-6.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed with results

Key Signals

80% success

Data Visualizations

Phase Distribution

5Total
Phase 1 (5)

Trial Status

Completed4
Terminated1

Trial Success Rate

80.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (5)

Research Network

Common Treatments

  • Amcenestrant1
  • Fexinidazole Hoe2391
  • Rilzabrutinib1
  • Tolebrutinib1
  • Venglustat1

Active Sponsors

  • Sanofi4
  • Principia Biopharma, a Sanofi Company1

Related Conditions

  • Healthy Volunteers1

Activity Timeline